Literature DB >> 18475516

NPC 15669 blocks neutrophil CD18 increase and lung injury during cardiopulmonary bypass in pigs.

J M Bator1, A M Gillinov, K J Zehr, J M Redmond, I C Wilson, A Herskowitz, J R Connor, R M Burch, D E Cameron.   

Abstract

During cardiopulmonary bypass (CPB), neutrophils become activated due to contact with extracorporeal surfaces and binding of complement fragments C3a and C5a, leading to extravasation and subsequent tissue damage. In this study, the effects of the leumedin NPC 15669 (N [9H - (2,7 dimethylfluorenyl - 9 - methoxy) car bonyl]-L-leucine), a leukocyte recruitment inhibitor, were evaluated in a pig model of CPB. NPC 15669 caused significant inhibition of CPB associated increase in CD18 upregulation, lung tissue myeloperoxidase content, and percentage wet weight compared to controls. Lung histology revealed clear airways and minimal neutrophil infiltration in treated animals vs. significant oedema and cellular infiltration in controls. It is concluded that CPB causes a dramatic increase in neutrophil CD18, and that leumedins are effective in inhibiting neutrophil activation and subsequent tissue injury when administered during CPB.

Entities:  

Year:  1993        PMID: 18475516      PMCID: PMC2365389          DOI: 10.1155/S0962935193000201

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  22 in total

1.  Complement activation and lung permeability during cardiopulmonary bypass.

Authors:  S D Tennenberg; C W Clardy; W W Bailey; J S Solomkin
Journal:  Ann Thorac Surg       Date:  1990-10       Impact factor: 4.330

2.  Two-step model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte beta 2 integrins in vivo.

Authors:  U H von Andrian; J D Chambers; L M McEvoy; R F Bargatze; K E Arfors; E C Butcher
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

3.  N-(fluorenyl-9-methoxycarbonyl) amino acids, a class of antiinflammatory agents with a different mechanism of action.

Authors:  R M Burch; M Weitzberg; N Blok; R Muhlhauser; D Martin; S G Farmer; J M Bator; J R Connor; M Green; C Ko
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

4.  NPC 15669 enhances survival and reverses leukopenia in endotoxin-treated mice.

Authors:  L Noronha-Blob; V C Lowe; M Weitzberg; R M Burch
Journal:  Eur J Pharmacol       Date:  1991-07-09       Impact factor: 4.432

5.  Inhibition of leukocyte adherence by anti-CD18 monoclonal antibody attenuates reperfusion injury in the rabbit ear.

Authors:  N B Vedder; R K Winn; C L Rice; E Y Chi; K E Arfors; J M Harlan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

6.  Assessment of leukocyte involvement during ischemia and reperfusion of intestine.

Authors:  M B Grisham; J N Benoit; D N Granger
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

7.  Perioperative alteration of neutrophil functions after open heart and other major surgeries. A comparative study.

Authors:  J Utoh; T Yamamoto; T Kambara; H Goto; Y Miyauchi
Journal:  J Cardiovasc Surg (Torino)       Date:  1989 Jul-Aug       Impact factor: 1.888

8.  Myeloperoxidase and elastase as markers of leukocyte activation during cardiopulmonary bypass in humans.

Authors:  M E Faymonville; J Pincemail; J Duchateau; J M Paulus; A Adam; G Deby-Dupont; C Deby; A Albert; R Larbuisson; R Limet
Journal:  J Thorac Cardiovasc Surg       Date:  1991-08       Impact factor: 5.209

9.  Leukocyte depletion ameliorates free radical-mediated lung injury after cardiopulmonary bypass.

Authors:  K Bando; R Pillai; D E Cameron; J D Brawn; J A Winkelstein; G M Hutchins; B A Reitz; W A Baumgartner
Journal:  J Thorac Cardiovasc Surg       Date:  1990-05       Impact factor: 5.209

10.  Monoclonal antibodies against porcine LFA-1: species cross-reactivity and functional effects of beta-subunit-specific antibodies.

Authors:  J E Hildreth; V Holt; J T August; M D Pescovitz
Journal:  Mol Immunol       Date:  1989-09       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.